BridgeMD
A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
EU CTIS ID: 2023-504303-86-00
What this study is testing
To evaluate the efficacy of atezolizumab plus bevacizumab compared with active surveillance on the basis of recurrence-free survival (RFS) as determined by an IRF
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants with a first diagnosis of HCC who have undergone either curative resection or ablation (RFS or MWA only) within 4-12 weeks prior to randomization
- High risk for HCC recurrence after resection or ablation
- Full recovery from surgical resection or ablation within 4 weeks prior to randomization
- Absence of MVI (Vp3 or Vp4)
- ECOG Performance Status of 0 or 1
- Child-Pugh Class A status
You likely can't join if
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Evidence of residual, recurrent, or metastatic disease at randomization
- On the waiting list for liver transplant
- History of hepatic encephalopathy
- Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization
- Have received more than 1 cycle of adjuvant TACE following surgical resection
The study team makes the final eligibility decision.
Where it's taking place
- Costa Rica
- China
- Japan
- Russian Federation
- Brazil
- Thailand
- Turkey
- Canada
- Mexico
- Hong Kong
- United States
- New Zealand
- Peru
- Taiwan
- Singapore
- Australia
- Korea, Republic of
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Costa Rica; China; Japan; Russian Federation; Brazil; Thailand and 11 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.